Since the first-generation CAR-Ts reached the market several years ago, clinicians have become more adept at handling ...

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines ...

Faced with the prospect of tariffs on imported medicines threatened by the Trump administration, Indian drugmaker Hikma has said it will spend $1 billion to expand its manufacturing and R&D operations ...

At Axtria Ignite 2025 in Princeton, New Jersey, web editor Nicole Raleigh spoke with the company’s co-founder, president, and CEO Jaswinder Chadha. An AI-first data analytics innovator focused on ...

BioCryst has agreed to sell its European business based on hereditary angioedema (HAE) therapy Orladeyo to Italy's Neopharmed Gentili in a deal valued at $250 million upfront. The transaction – which ...

In June 2022, NHS England (NHSE) and the National Institute for Health and Care Excellence (NICE) launched the Innovative Medicines Fund (IMF). The £340 million fund will provide non-cancer ...

A long-awaited report from the US Federal Trade Commission (FTC) on pharmacy benefit managers (PBMs) is out – and will make uncomfortable reading for the pharma supply chain middlemen.

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

In today’s pharmaphorum podcast, Orr Inbar, co-founder and CEO of QuantHealth, a Tel Aviv-based AI-powered clinical trial design company, discusses how advances in data and AI can help.

Company Drug Indication Stage; Mitsubishi Tanabe Pharma: MT-5562: Systemic sclerosis: Preclinical: Bridge Biotherapeutics: BBT-877: IPF: Phase 2: Blade Therapeutics ...

Explore the potential threats and risks impacting the pharmaceutical industry in 2024, including considerations such as protests, risk analysis, and the influence of environmental, social, and ...

Explore the latest advancements and challenges in ADC therapy at AACR 2025: New modalities and remaining challenges. Stay updated on the newest developments in the field.